M&A

M&A
Product Description

With over 29 years of experience and operating across all key life science sectors, PharmaVentures offers deep sector expertise to support your M&A and funding transactions.

We support our clients with strategic advice and full end-to-end process management capabilities to achieve best outcome from their strategic transactions. Our services range from identifying acquisition targets, to advising on the exit strategy, to fundraising, restructuring advice and other capital solutions.
PharmaVentures is a dedicated life science focused advisory firm with deep expertise and connectivity across the life sciences spectrum.  Our dedicated advisory team has decades of experience advising clients on successful M&A processes in highly complex transactions.

We use our team’s collective intellectual capital, specialist sector and product expertise, and wealth of experience to deliver the best long-term solutions for our clients. We understand and respect the different requirements of shareholders, management, and other stakeholders. We work closely with our global clients, helping them achieve their strategic objectives and derive optimal value from their M&A transactions.

Read more Show less

PHARMAVENTURES LTD

  • GB
  • 2020
    On CPHI since
  • 25 - 49
    Employees
Company types
Consultancy
View company profile
Categories
more categories Show less
Sales Markets
Show more Show less

PHARMAVENTURES LTD

  • GB
  • 2020
    On CPHI since
  • 25 - 49
    Employees
Company types
Consultancy
View company profile

More Products from PHARMAVENTURES LTD (2)

  • Licensing

    Product Licensing

    Top tier pharmaceutical companies, biotechs, diagnostics, medtech, healthcare IT and life science research companies, universities and technology transfer agencies have trusted​​ us to deliver the best licensing deals for their assets. 
  • Fundraising

    Product Fundraising

    Operating across all key life science sectors, PharmaVentures offers deep sector expertise to help you derive optimal value from your funding transactions.

    We support our clients with strategic advice and full end-to-end process management capabilities to achieve the best outcome from their stra...

PHARMAVENTURES LTD resources (2)

  • Size doesn’t matter: How smaller deals are shaping healthcare M&A

    Sponsored Content Size doesn’t matter: How smaller deals are shaping healthcare M&A

    Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With ample capital available in the sector, it comes as no surprise that PwC forecasts M&A deals will reach $400 billion this year.  
    12 Apr 2022
  • CPHI Webinar Series How is M&A Shifting the Pharma Manufacturing Landscape?

    Webinar CPHI Webinar Series How is M&A Shifting the Pharma Manufacturing Landscape?

    What will this webinar address? Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape. Partnerships and mergers are a key tool for adding value to pharmaceutical companies; helping to navigate technological limitations, address portfolio challenges and chase innovation. This webinar, delivered in partnership with PharmaVentures, will examine the trends and developments driving deal-making in the current market. When you attend this webinar, you will discover: The key acquisition drivers for Pharma Manufacturers and CDMOs (tech, therapy areas, patent losses, portfolio challenges) What does the future look like? Prior to the COVID-19 pandemic, M&A activity in pharmaceuticals was soaring with $414 billion worth of deals in 2019 . What will the short to mid-term impact be on deal-making? How is ‘reshoring’ transforming the pharma manufacturing map and impacting Governments?
    2022-05-11